Wick W, Furnari F B, Naumann U, Cavenee W K, Weller M
Department of Neurology, University of Tübingen, Germany.
Oncogene. 1999 Jul 8;18(27):3936-43. doi: 10.1038/sj.onc.1202774.
The tumor suppressor gene PTEN (MMAC1, TEP1) encodes a dual-specificity phosphatase and is considered a progression-associated target of genetic alterations in human gliomas. Recently, it has been reported that the introduction of wild type PTEN into glioma cells containing endogenous mutant PTEN alleles (U87MG, LN-308), but not in those which retain wild-type PTEN (LN-18, LN-229), causes growth suppression and inhibits cellular migration, spreading and focal adhesion. Here, we show that PTEN gene transfer has no effect on the chemosensitivity of the four cell lines. Further, a correlational analysis of the endogenous PTEN status of 12 human glioma cell lines with their sensitivity to seven different cancer chemotherapy drugs reveals no link between PTEN and chemosensitivity. In contrast, ectopic expression of wild type PTEN, but not the PTEN(G129R) mutant, in PTEN-mutant gliomas markedly sensitizes these cells to irradiation and to CD95-ligand (CD95L)-induced apoptosis. PTEN-mediated facilitation of CD95L-induced apoptosis is associated with enhanced CD95L-evoked caspase 3 activity. Protein kinase B (PKB/Akt), previously shown to inhibit CD95L-induced apoptosis in nonglial COS7 cells, is inactivated by dephosphorylation. Interestingly, both PTEN-mutant U87MG and PTEN-wild-type LN-229 cells contain phosphorylated PKB constitutively. Wild-type PTEN gene transfer promotes dephosphorylation of PKB specifically in U87MG cells but not in LN-229 cells. Sensitization of U87MG cells to CD95L-apoptosis by wild-type PTEN is blocked by insulin-like growth factor-1 (IGF-1). The protection by IGF-1 is inhibited by the phosphoinositide 3-OH (PI 3) kinase inhibitor, wortmannin. Although PKB is a down-stream target of PI 3 kinase, the protection by IGF-1 was not associated with the reconstitution of PKB phosphorylation. Thus, PTEN may sensitize human malignant glioma cells to CD95L-induced apoptosis in a PI 3 kinase-dependent manner that may not require PKB phosphorylation.
肿瘤抑制基因PTEN(MMAC1,TEP1)编码一种双特异性磷酸酶,被认为是人类胶质瘤中与进展相关的基因改变靶点。最近有报道称,将野生型PTEN导入含有内源性突变PTEN等位基因的胶质瘤细胞(U87MG,LN - 308)中会导致生长抑制,并抑制细胞迁移、铺展和粘着斑,但导入保留野生型PTEN的细胞(LN - 18,LN - 229)中则无此作用。在此,我们表明PTEN基因转移对这四种细胞系的化学敏感性没有影响。此外,对12种人类胶质瘤细胞系的内源性PTEN状态与其对七种不同癌症化疗药物的敏感性进行相关性分析,结果显示PTEN与化学敏感性之间没有关联。相反,在PTEN突变的胶质瘤中异位表达野生型PTEN而非PTEN(G129R)突变体,可使这些细胞对辐射和CD95配体(CD95L)诱导的凋亡明显敏感。PTEN介导的对CD95L诱导凋亡的促进作用与CD95L诱发的半胱天冬酶3活性增强有关。蛋白激酶B(PKB/Akt)先前已被证明在非神经胶质COS7细胞中可抑制CD95L诱导的凋亡,它通过去磷酸化而失活。有趣的是,PTEN突变的U87MG细胞和PTEN野生型的LN - 229细胞中均持续含有磷酸化的PKB。野生型PTEN基因转移仅在U87MG细胞中特异性地促进PKB的去磷酸化,而在LN - 229细胞中则无此作用。野生型PTEN使U87MG细胞对CD95L诱导的凋亡敏感的作用被胰岛素样生长因子-1(IGF - 1)阻断。IGF - 1的保护作用被磷酸肌醇3 - OH(PI 3)激酶抑制剂渥曼青霉素抑制。尽管PKB是PI 3激酶的下游靶点,但IGF - 1的保护作用与PKB磷酸化的恢复无关。因此,PTEN可能以一种PI 3激酶依赖的方式使人类恶性胶质瘤细胞对CD95L诱导的凋亡敏感,这种方式可能不需要PKB磷酸化。